RSC Bay Area Is First in the Nation to Deploy FDA-Cleared AI for Embryo Assessment by Alife Health, Pioneering a New Standard in IVF Care

▤ Summary

Alife Health and RSC Bay Area announced the first U.S. clinical deployment of Embryo Predict, an FDA-cleared AI tool for embryo assessment. The tool analyzes embryo images and gives embryologists an objective score to support transfer decisions in IVF. RSC Bay Area says the rollout follows years of partnership work with US Fertility and Alife, including integration, training, and data readiness. The announcement positions the clinic as an early adopter of AI-driven fertility care and highlights the tool’s commercial availability in the U.S., Europe, and the U.K.

▦ Linked Companies

Alife Health

$1M to $5M